Drug Target Review

Skip to main content
Skip to navigation

Featured content

Drug Target Review launches new website designed for drug discovery professionals

2026-04-30T07:00:00+01:00

Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that provides full access to premium analysis, reports and expert commentary.

Article
From constraint to catalyst: innovation in rare disease clinical development
2026-04-29T07:00:00+01:00By Dr Gen Li
Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence generation, trial design and regulatory thinking that could influence the future of clinical development.
Article
Why lower organisms matter for neurodegeneration drug discovery
2026-04-27T07:00:00+01:00By Dr Christopher Saunter
In the wake of recent government policy aimed at actively replacing animal models in drug discovery, we consider a possible solution to the translational shortfalls of current cellular methodologies for neurodegenerative disease.
Article
Variant or viable target? How resolving complex genomic regions is reshaping rare disease therapeutics
2026-04-23T07:30:00+01:00By Dr Aaron Wenger
Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Previous
Next

Webinars

Previous
Next

Whitepapers

Previous
Next